[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anaemia-in-childbirth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anaemia-in-childbirth":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100458582","phase-3-ferric-derisomaltose-iron-isomaltoside-versus-iron-sucrose-for-treatment-of-iron-deficiency-in-pregnancy-100458582",false,"NCT05251493","Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy","Intravenous Iron Isomaltoside Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy: A Randomized Comparative Trial","Inclusion Criteria:\n\n* 18 years of age and over\n* Pregnancy with Gestational age ≥13 weeks\n* Iron deficiency anemia defined as:\n* Hemoglobin less than or equal to 110g\u002FL and\n* Serum ferritin less than 30ng\u002FmL or\n* Iron Saturation (Iron\u002FTIBC) less than 20%\n* Willing to participate and attend all planned follow up visits\n* Willing to sign informed consent form\n* Willing to attend appointments for iron infusion and follow up visits\n* Willing to attend all planned bloodwork appointments\n\nExclusion Criteria:\n\n* Pregnancy GA less than 13 weeks\n* History of anemia caused by thalassemia or other haematologic disorder other than iron deficiency anemia ,\n* Known serious hypersensitivity to other parental iron products\n* Iron overload or disturbances in utilization of iron (i.e, haemochromatosis and haemosiderosis)\n* Decompensated liver cirrhosis or active hepatitis\n* History of multiple allergies\n* Active acute or chronic infections\n* Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion\n* Current participation in any other interventional trial\n* Multiple gestation pregnancy\n* Significant comorbidities (asthma requiring daily therapy or other lung diseases)\n* Heart disease\n* Kidney disease\n* Rheumatologic disease\n* Cancer\n* Known hypersensitivity to iron sucrose or any excipients\n* Known hypersensitivity to iron isomaltoside or any excipients.",true,"FEMALE","18 Years","50 Years",{"count":21,"type":22},280,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion.\n\nThe goal of this clinical trial:\n\n* Correct IDA with fewer visits and less impact on the healthcare system\n* Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.",[28],"Iron Deficiency Anaemia in Childbirth",[30,31],"quality of life","anemia","RECRUITING","2025-05-12",{"date":35,"type":36},"2025-05-15","ACTUAL",{"date":38,"type":36},"2022-06-06",{"date":40,"type":22},"2027-02-28",{"name":42,"class":43},"Saskatchewan Health Authority - Regina Area","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100583650","maternal-iron-deficiency-and-childhood-health-100583650","NCT06879080","Maternal Iron Deficiency and Childhood Health","Maternal Iron Deficiency and Childhood Health- a Prospective Cohort Study","MATILDA","Inclusion Criteria:\n\n* Pregnant\n* Can read and write Finnish, Swedish or English\n\nExclusion Criteria:\n\n* Illiterate",{"count":54,"type":22},6000,"OBSERVATIONAL","The aim of this prospective observational cohort study is to study maternal iron deficiency and iron deficiency anemia and the use of iron supplements in pregnancy and their impact on the health of the offspring and pregnancy outcomes.\n\nAll women coming to Tampere University Hospital for prenatal checkups and\u002For labor are recruited to the study. After giving their consent the mothers fill an online questionnaire about about possible maternal anemia and its diagnosis in pregnancy, iron deficiency and its diagnosis in pregnancy, maternal use of iron supplement or folic acid and it´s timing, about possible other chronic disease and their medications during pregnancy, and whether the mother has got intravenous iron infusions in pregnancy. Mothers also give their permit to use their in-and outpatient data from pregnancy until hospital discharge and to follow the health of their offspring from birth until 7 years of age from in- and outpatient records.We aim to recruit 6000 mother-child-pairs.\n\nThe health of the offspring (growth, diagnoses, medication, possible therapies, need of support at daycare or school) will be followed for the first month, then at 1,5 years, four years and seven years of age from the patient records.\n\nIn addition to the cohort study, two nested cohort studies will be performed. The aim of the nested cohort studies is to study the correlation of maternal iron status to the iron status of the child. Secondary aim is to evaluate iron biomarkers, especially reticulocyte hemoglobin, and their reliability to interpret neonatal iron status.\n\nA 100 mothers with diagnosed iron deficiency and iron supplementation (p.o. or i.v.) in pregnancy, are recruited to Nested cohort 1. For the nested cohort 2, a 100 mothers with diabetes requiring insulin therapy in pregnancy are recruited. Tor these two cohorts, a 100 mothers without iron deficiency or diabetes will be recruited as controls. Iron status of the mother will be tested before delivery from blood sample. The iron status of the offspring will be checked from umbilical blood, at 2 days of age at the same time other lab tests are taken, at eight months and two and five years of age. In addition to the laboratory tests, parents fill up an electronical questionnaire at eight months, two and five years about the nutrition, sleep, behaviour and cognitive and motor skills of their child.\n\nThe researchers try to find out, whether iron deficiency in pregnancy has long-term effects on the health and development of the offspring, and how the iron status correlates between the mother and the child, and does it have impact on their sleep, behaviour or skills.",[28,58,59,60,61],"Iron Deficiency","Iron Deficiency in Pregnancy","Iron Deficiency Anemia in Pregnancy","Iron Status",[63],"iron deficiency, iron deficiency anemia, pregnancy, pregnancy outcomes, health of the offspring","2025-03-11",{"date":66,"type":36},"2025-03-17",{"date":68,"type":36},"2024-04-22",{"date":70,"type":22},"2034-12-31",{"name":72,"class":43},"Tampere University Hospital"]